Conjunctival Lymphoma

Lymphoma of the conjunctiva is an ocular malignancy derived from clonal proliferation of lymphocytes. The majority of conjunctival lymphoma is extranodal marginal zone B-Cell lymphoma (EMZL), however diffuse large B-cell (DLBCL), follicular (FL), mantle cell (MCL) and T- cell subtypes are also seen....

Full description

Saved in:
Bibliographic Details
Published in:Eye (London) 2023-04, Vol.37 (5), p.837-848
Main Authors: McGrath, Lindsay A., Ryan, David A., Warrier, Sunil K., Coupland, Sarah E., Glasson, William J.
Format: Article
Language:English
Subjects:
59/78
692/699/3161/3162
692/699/67/1484
692/699/67/1990/291
82/51
96/31
96/63
Antigens
Antineoplastic Agents - therapeutic use
B-cell lymphoma
Cancer
CD20 antigen
Classification
Conjunctiva
Conjunctiva - pathology
Conjunctival Neoplasms - drug therapy
Conjunctival Neoplasms - therapy
Eye Neoplasms
Humans
Immunomodulation
Laboratory Medicine
Lymphocytes
Lymphocytes B
Lymphoma
Lymphoma - pathology
Lymphoma, B-Cell, Marginal Zone - drug therapy
Lymphoma, B-Cell, Marginal Zone - therapy
Malignancy
Medicine
Medicine & Public Health
Monoclonal antibodies
Next-generation sequencing
Ophthalmology
Pharmaceutical Sciences/Technology
Review
Review Article
Rituximab
Rituximab - therapeutic use
Surgery
Surgical Oncology
Systemic diseases
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lymphoma of the conjunctiva is an ocular malignancy derived from clonal proliferation of lymphocytes. The majority of conjunctival lymphoma is extranodal marginal zone B-Cell lymphoma (EMZL), however diffuse large B-cell (DLBCL), follicular (FL), mantle cell (MCL) and T- cell subtypes are also seen. Clinical manifestations are non-specific, but include unilateral or bilateral painless salmon-pink conjunctival lesions. Approaches to treatment have centered around local immunomodulation, often with Interferon-α2b or Rituximab (anti-CD20 monoclonal antibody) with or without radiation. Although conjunctival lymphoma is generally considered an indolent disease, recent advances in next-generation sequencing have improved clinicians’ ability to predict future recurrence or systemic disease through assessment of cytogenic and molecular features. In this paper, we review the classification, clinical features, diagnostic techniques, and emerging strategies for management and prognostication of conjunctival lymphomas.
ISSN:0950-222X
1476-5454
DOI:10.1038/s41433-022-02176-2